GSK plc announced yesterday it has started shipping its quadrivalent influenza vaccines to U.S.-based healthcare providers and pharmacies in preparation for the 2022-23 season. GSK expects to distribute over 50 million doses of its innovative flu shots in the USA.
Both FLULAVAL QUADRIVALENT and FLUARIX QUADRIVALENT will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for patients six months and older in line with U.S. CDC recommendations.
Source: 2022-23 Influenza Vaccines Arriving in the USA — Precision Vaccinations